Stewart Alan Factor

Affiliations: 
Emory University, Atlanta, GA 
Area:
Movement Disorders
Google:
"Stewart Factor"
Mean distance: 53433
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Espay AJ, Guskey MT, Norton JC, et al. (2018) Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Movement Disorders : Official Journal of the Movement Disorder Society
Fox SH, Metman LV, Nutt JG, et al. (2017) Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society
McGarry A, McDermott M, Kieburtz K, et al. (2016) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology
Frank S, Testa CM, et al. (2016) Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. Jama. 316: 40-50
Factor SA, Hatcher-Martin JM, Morse AS, et al. (2016) Freezing of gait that disappears: Should there be rest before rehab? Parkinsonism & Related Disorders
Comella CL, Perlmutter JS, Jinnah HA, et al. (2016) Clinimetric testing of the comprehensive cervical dystonia rating scale. Movement Disorders : Official Journal of the Movement Disorder Society
Carvalho JO, Long JD, Westervelt HJ, et al. (2016) The impact of oculomotor functioning on neuropsychological performance in Huntington disease. Journal of Clinical and Experimental Neuropsychology. 38: 217-226
Sampat R, Young S, Rosen A, et al. (2016) Potential mechanisms for low uric acid in Parkinson disease Journal of Neural Transmission. 1-6
Mata IF, Jang Y, Kim CH, et al. (2015) The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Molecular Neurodegeneration. 10: 50
O'Brien CF, Jimenez R, Hauser RA, et al. (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1681-7
See more...